Matches in Nanopublications for { ?s ?p "[We describe treatment of a refractory, progressive Li-Fraumeni syndrome embryonal carcinoma with a p53 therapy (Advexin) targeted to the underlying molecular defect of this syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP226811.RA8TXFTpF2n58QBRd5iyeoRoSSVBlYu7O5oFthjtp7GKs130_assertion description "[We describe treatment of a refractory, progressive Li-Fraumeni syndrome embryonal carcinoma with a p53 therapy (Advexin) targeted to the underlying molecular defect of this syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP226811.RA8TXFTpF2n58QBRd5iyeoRoSSVBlYu7O5oFthjtp7GKs130_provenance.
- NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_assertion description "[We describe treatment of a refractory, progressive Li-Fraumeni syndrome embryonal carcinoma with a p53 therapy (Advexin) targeted to the underlying molecular defect of this syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP751909.RA-LyFaBpnBWCp2Jr8qfPtTecV_Bncdrtfrs6rK8oKBtA130_provenance.
- NP608528.RA0E9YL7-wHHfkP_5PaJU94O9_5A0qHORJ326G-lswzbs130_assertion description "[We describe treatment of a refractory, progressive Li-Fraumeni syndrome embryonal carcinoma with a p53 therapy (Advexin) targeted to the underlying molecular defect of this syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP608528.RA0E9YL7-wHHfkP_5PaJU94O9_5A0qHORJ326G-lswzbs130_provenance.
- NP608529.RAyKAFLriRGdS-z5_SFSZIrJeWh_pvhlM412hbE5XMtSg130_assertion description "[We describe treatment of a refractory, progressive Li-Fraumeni syndrome embryonal carcinoma with a p53 therapy (Advexin) targeted to the underlying molecular defect of this syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP608529.RAyKAFLriRGdS-z5_SFSZIrJeWh_pvhlM412hbE5XMtSg130_provenance.